Rhea Fertility has acquired Tilly, a digital fertility health company founded in 2019 by Anna Sane and Jenny Ann Axson Johnson. Tilly provides evidence-based mental health tools and comprehensive treatment tracking for infertility patients. The acquisition aims to integrate evidence-based psychosocial support into fertility care across Rhea’s global network of clinics.
“Research consistently shows that the emotional toll is one of the primary reasons fertility patients discontinue treatment. Our platform removes barriers to accessing proven support, ensuring that patients receive the care they need throughout their journey,” said Jenny Ann Axson Johnson, Co-Founder of Tilly.
Tilly has been collaborating with fertility clinics across Europe and the U.S., providing digital mental health solutions tailored to fertility patients. Anna Sane, Co-Founder of Tilly, commented, “We have seen the most significant improvements in patient well-being when our tools are seamlessly integrated into the fertility care process. Recognizing the need for greater consolidation in the fertility market, we are thrilled to join Rhea Fertility and contribute to its comprehensive reproductive health ecosystem.”
Margaret Wang, CEO of Rhea Fertility, stated, “We were highly impressed by the platform and content developed by Tilly. As part of our commitment to enhancing the patient experience within our GenPrime clinics, we recognize that psychosocial support is a critical component of the fertility journey.”
The acquisition follows Rhea’s recent purchase of Embryonics, an advanced suite of AI-powered diagnostic tools. Rhea Fertility operates a global network of owned and partner clinics under the GenPrime brand, powered by Rhea Labs – a technology-driven platform utilizing data and insights to accelerate innovation and enhance patient outcomes.